Navigation Links
3SBio Inc. Announces Unaudited Second Quarter Results
Date:8/17/2010

icense approval, while Nuleusin, a treatment for late stage metastatic renal cell carcinoma, is still under review. Events Subsequent to June 30, 2010 Following the completion of construction of the new EPIAO and TPIAO plant in the first quarter, the SFDA granted Good Manufacturing Practice ("GMP") certification in August 2010. GMP certification will support the future growth of EPIAO and TPIAO in China and serve as an important step towards exploring global biosimilar opportunities. -- Dr. Jing Lou, chief executive officer of 3SBio, commented: "Overall, the business is performing as expected with a strong set of results this quarter and first half and we reiterate our full-year revenue guidance of US$56-60 million. EPIAO's market share by value in the first quarter of 2010 reached an all-time high of 43.3% and for the first time, TPIAO sales accounted for more than 30% of net revenues, providing further evidence that we are successfully diversifying our product mix. We are also pleased to announce that our new EPIAO and TPIAO plant was inspected by the SFDA in July and has been formally certified as GMP compliant. This is a significant milestone for us as we focus on growing our business in China while taking important steps towards exploring global biosimilar opportunities. "

Three months ended June 30, 2010 Unaudited Financial Results

Net revenues. Net revenues increased by 29.5% to RMB105.5 million (US$15.6 million) for the second quarter of 2010 from RMB81.5 million (US$11.9 million) for the same period in 2009. This increase was largely due to continued strength from EPIAO and TPIAO products which increased by 22.9% and 44.6%, respectively, over the same period in 2009. TPIAO remained the Company's second largest revenue contributor in the quarter, accounting for 30.5% of total net revenues. Export sales declined by 16.9% to RMB2.9 million (US$0.4 million), and revenues from our IV Iron Sucrose supplement rose 5
'/>"/>

SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. 3SBio Inc. Announces Second Quarter 2008 Results
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. 3SBio Inc. Announces Results of Annual General Meeting
5. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
6. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
7. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
8. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
9. 3SBio Inc. Files for SFDA Approval of NuLeusin
10. 3SBio Inc. Announces Third Quarter 2008 Results
11. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014  Having the right people ... vital to accelerating business growth and achieving clinical and ... Association (AHA) Leadership Summit, July 20-22, 2014, in ... of hospital executives and healthcare experts discussing how partnerships ... Carrocino , President & Chief Executive Officer of Cape ...
(Date:7/23/2014)... StemGenex® , the leading resource for ... at improving the lives of patients dealing with degenerative ... disease. StemGenex believes that a commitment to the ... when providing care to patients with degenerative diseases. ... accessible to the millions of individuals currently living with ...
(Date:7/23/2014)... Iowa (PRWEB) July 23, 2014 DuPont ... the business as vice president of Agricultural Biotechnology (ABT), ... Biotechnology where he served most recently as president, chief ... biotechnology and business leadership in the seed and crop ... said Paul E. Schickler , president of DuPont ...
(Date:7/23/2014)... -- regulated information -- UCB today announced an important ... positive topline results from the latest Phase 3 ... to evaluate the efficacy and safety of ... compared to placebo, as adjunctive treatment in adult ... controlled despite treatment with one or two concomitant ...
Breaking Biology Technology:MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
... N.C., Dec. 8, 2010 Pharmaceutical Institute, ... pharmaceutical and biotech industry and a subsidiary of Campbell ... Hospital Marketplace e-course series.  It ... and Institutional IT Systems ...
... 8, 2010 Reportlinker.com announces that a new ... Merck KGaA: PharmaVitae Profile ... IntroductionThis analysis examines the historical and forecast ... sector. The profile encompasses global company strategy, portfolio ...
... 8, 2010 Aquatic Energy LLC announced today that ... Zulandi, have joined its Board of Directors.  "Our new ... experience to our company," stated David Johnston, CEO of ... time, as the company moves from proof-of-concept demonstration facilities ...
Cached Biology Technology:Hospital Marketplace E-Course Suite Adds Insight on Quality and Information Systems 2Reportlinker Adds Merck KGaA: PharmaVitae Profile 2Senior Energy Executives Join Aquatic Energy Board 2Senior Energy Executives Join Aquatic Energy Board 3
(Date:7/23/2014)... The U.S. Environmental Protection Agency (EPA) today ... the University of Massachusetts Amherst School of Public ... three-year, $700,000 Science to Achieve Results (STAR) grant ... by Native subsistence hunters in subarctic North America ... exposure and to provide culturally-relevant recommendations for mitigation. ...
(Date:7/23/2014)... fable about the crow and the pitcher, a thirsty bird ... to drink from it, he finds the water level out ... pitcher, the bird drops pebbles into it one at ... him to drink his fill. , Highlighting the value of ... more effective than brute force. It also characterizes crows as ...
(Date:7/23/2014)... Defense recently awarded the STEMPREP Project at Southern ... its goal of increasing the number of minorities ... middle school students for the two-summer classroom phase ... students with summer opportunities at research labs. , ... School of Education and Human Development, boasts an ...
Breaking Biology News(10 mins):Studying impacts of indoor air pollution on tribal communities 2Studying impacts of indoor air pollution on tribal communities 3Smarter than a first-grader? 2Smarter than a first-grader? 3Smarter than a first-grader? 4Department of Defense awards $2.6 million grant to SMU STEM program for minority students 2
... are common, but few studies of lung nodule identification ... Researchers from Kaiser Permanente Southern California identified 7,112 patients ... information within the electronic medical record. Their ... International Association for the Study of Lung Cancer,s (IASLC) ...
... Your genes determine much about you, but environment can ... with consequences that can last a lifetime. In a ... ), researchers have for the first time shown that the ... the chemical modifications to DNA we are born with, that ...
... some cases of the progressive fatal neurological disease amyotrophic ... disease. Shedding light on how ALS destroys the cells ... in this gene affect the structure and growth of ... cells responsible for controlling muscles. People with ALS experience ...
Cached Biology News:Differences between human twins at birth highlight importance of intrauterine environment 2New gene mutations linked to ALS and nerve cell growth dysfunction 2New gene mutations linked to ALS and nerve cell growth dysfunction 3
... enterprise microarray informatics platform for microarray data storage, ... and use it forever without paying ongoing license ... Acuity has all the analysis tools you need ... quality control statistics and normalization, all the way ...
... industry standard microarray image analysis software because ... analysis tools, visualizations, automation capabilities, performance and ... with every GenePix scanner, and it also ... all types of arrays. A wide range ...
A univariate (peak height or area) quantitative multi-component analysis package....
... H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH 2 (Disulfide ... peptide and 1 ... I-labelled peptide, please see ... ([ 1 2 ...
Biology Products: